The only reason Mithra included such a high % of Mayne is we had no money. The Teva deal $900m ( disaster) hurt so much. Still a possible little pain yet . Had the Nuvaring generic been FDA approved 2019 as expected we would be considerably more comfortable. This Esterol does appear to be a winner. Had we had more cash we may have negotiated Mithra deal from position of strength. Although Richards skills in this area may be limited. ( Inter Company). His own personal deal making from Mayne board are excellent.
MYX Price at posting:
37.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)